Earnings Feed
Start Free
Axsome Therapeutics, Inc.·4

Jan 2, 7:02 PM ET

Saad Mark E 4

4 · Axsome Therapeutics, Inc. · Filed Jan 2, 2026

Insider Transaction Report

Form 4
Period: 2025-12-31
Axsome Therapeutics, Inc.AXSM
Saad Mark E
Director
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2025-12-31$8.02/sh+6,231$49,973→ 16,233 total
  • Sale

    Common Stock

    [F2][F3][F4]
    2025-12-31$165.18/sh−6,231$1,029,237→ 10,002 total
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2025-12-31$4.95/sh+31,346$155,163→ 41,348 total
  • Sale

    Common Stock

    [F2][F3][F4]
    2025-12-31$165.18/sh−31,346$5,177,732→ 10,002 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F2]
    2025-12-31−6,231→ 0 total
    Exercise: $8.02From: 2017-05-27Exp: 2026-05-27→ Common Stock (6,231 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F2]
    2025-12-31−31,346→ 0 total
    Exercise: $4.95From: 2018-03-15Exp: 2027-03-15→ Common Stock (31,346 underlying)
Holdings

  • Common Stock

    [F5]
    (indirect: See explanation 5 below.)
    300
Footnotes (5)
  • [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options.
  • [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
  • [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
  • [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09.
  • [F5]Represents additional shares held indirectly by the Reporting Person prior to December 31, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Signature
/s/ Nick Pizzie, Attorney-in-Fact|2026-01-02

Documents

1 file
  • 4
    ownership.xmlPrimary

    4